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of tandem repeats (VNTR) with a ma-
ximum sensitivity of 0,5% in 44 evaluable
follow-ups. AI was used in 11 patients/12
follow-ups (ALL 3, AML 5, CML 2, JMML
1/2). The treatment was started on the ba-
sis of increasing mixed chimerism
(inMC;7), in molecular relapse (1) or in he-
matological relapse (4). Withdrawn
of post-transplant immunosuppression
was performed in 9 patients, 5 patients
received second-line therapy by donor
lymphocyte infusion (DLI) and in 3 follow-
ups DLI was applied as a front-line
therapy. AI was combined with
chemotherapy (CHT) in 2 children. CD3+
doses varied between 1x1 05 and 2,4x108/kg
body weight according to type of donor
and indication for DLI.
Results: Complete donor chimerism
(CC) characterized by the disappearance
of recipient cells until day (0)+28
and sustained emergence of donor cells
was documented in 25/44 follow-ups.
Mixed chimerism (MC) characterized
by the re-emergence or persistence of re-
cipient cells after 0+28 was found
in 19/44 follow-ups. Transient MC (trMC)
was detected in 7, inMC in 12 follow-ups,
respectively. Transplant related mortality
(TRM) until 0+100 was 7/25 in CC
and 1/19 in MC group, respectively;
36 patients were therefore evaluable
for relapse free survival (RFS). At a me-
dian follow-up of 19 months (range
2 to 51 months) RFS for CC group was
17/18, whilst that for MC group was 7/18.
Hematological relapse was documented
in 1/7 children with trMC, in 1 patient
molecular relapse was detected and AI
was started before the appearance
of trMC. InMC was followed by hema-
tological relapse in 9/12 follow-ups,
3/12 patients with inMC responded to AI
and re-achieved CC. Complete response
to AI was defined as sustained recurrence
of CC and CCR was documented
in 4/12 children (1 AML, 2 CML, 1 JMML)
at a median follow-up of 30 months (range
15 to 40 months), 1 patient (ALL) achieved
CC but died due to severe graft-versus-
host disease. Three patients (2 AML,
1 JMML) showed transient decrease
or disappearance of MC and developed
hematological relapse SUbsequently, 8, 9
and 20 months after the first intervention
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with AI. No response was seen
in 4/12 follow-ups (2 ALL, 2 AML).
Conclusions: Detailed and frequent
monitoring of HC allows identification
of patients with high risk for hematological
relapse and therefore indicated for AI.
At least in some children with leukemia
it is possible to prevent hematological
relapse using AI when the intervention
comes early.
This work was suppol1ed by grants IGA-
MZ GR NC 6512-3 and IGA-MZ GR NC
5902-3.
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ADOPTIVE IMMUNOTHERAPY
OF POST-TRANSPLANT HEMA-
TOLOGICAL CML RELAPSE WITH
DONOR LYMPHOCYTE INFUSION
AND INTERFERON-a
A. Pieczonka\ J. Wachowiak\
D. Boruczkowski1 , M. Leda\ D. tadon2 ,
J. J6fkowska2 , M. Witt2
1 HSCT Unit, Institute of Pediatrics,
University of Medical Sciences, Poznan,
Poland
2 Institute of Human Genetics, Polish
Academy of Sciences, Poznan, Poland
Purpose: To evaluate the preliminary
results obtained with donor CD3
lymphocyte infusion (DLI) and interferon-a
(INF-u) in children with hematological CML
relapse occurring after allogeneic bone
marrow transplantation (allo-BMT)
Patients and methods: Between 1998-
2000 three children with CML underwent
allo-BMT from HLA-identical sibling and
developed hematological leukemia
relapse, which has been treated with DLI
and INF-a.
Conclusion: DLI + INF-a seems to offer
relatively effective and safe therapeutic
option for advanced types of CML relapse
occurring after allo-BMT in children, but
further long lasting follow-up is necessary
to define its place in management of post-
transplant leukemia relapse.
This work was suppol1ed by the State
Committee for Scientific Research -
Project No 6 POSE 050 21.
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UPN18 UPN 26 UPN 45
CML phase pre-BMT II CP ICP I CP
Donor/recipient sex F/F MIM M/F
Conditioning regiment BU16+Vp30+Cy120 Bu16+Vp30+Cy120 Bu16+Cy120
tor BMT
GvHD praphylaxis Csa + MTX Csa + MTX Csa + MTX
GvHD occurrences after Not observed Not observed II o (skin)
BMT
Relapse after BMT +76 m-c +52 m-c +23 m-c
Hematological - AP Hematological - AP Hematological - CP
Relapse therapy prior DLI HU HU + INF-a. HU
DLI I 1,0 x 108 I 3,0 X 107 I 0,5 X 108
(donor CD3 dose/kg II 1,0 x 108 II 0,5 x 108
III 1,0 x 108
INF-a. after DLI (+) (+) (+)
Evaluation ot efficacy and moditication ot the treatment have been based on results ot FISH
tor Philadelphia chromosome detection and cellular chimerism in case ot sex-mismatch.
Results: UPN18 UPN 26 UPN 45
GvHD not observed not observed not observed
Pancytopenia observed not observed observed
Time trom 1st DLI - + 162 +618
to cytogenetic remision
Disease status at last Hematol. remission Hematol. remission Hematol. remission
tollow up (10%) Ph+ (FI8H) (10%) Ph+ (FI8H) (7%) Ph+ (FI8H)
tram day +665 trom day +532 tram day +1108
22 months 17,7 months 37 months
8.
MONITORING OF MINIMAL RESI-
DUAL DISEASE (MRD) AND HEMA-
TOPOIETIC CHIMERISM WITH
SEVERAL COMPLEMENTARY GE-
NETIC METHODS IN CHILDREN
TREATED WITH ADOPTIVE IMMUNO-
THERAPY FOR POST-TRANSPLANT
HEMATOLOGICAL CML RELAPSE
D. Ładoń 1 , J. Jółkowska 1 , A. WOjda1 ,
A. Pieczonka2 , D. Boruczkowski2 ,
M. Leda1,2, J. Wachowiak2 , M. Witt1
1 Institute ot Human Genetics, Polish
Aeademy ot Scienees and 2 Department
ot Pediatrie Hematology and Oneology,
University ot Medieal Scienees, Poznań,
Poland
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The aim ot this study was to compare
results ot MRD and hematopoietie
ehimerism obtained by several moleeular
methods (FISH, RT-PCR, STR-PCR)
in children with post-transplant CML
relapse treated with adoptive immuno-
therapy. Genomie DNA was isolated trom
trozen whole peripheral blood by salting-
out method, amplitied with tluorescent
polymerase ehain reaetion primers
(speeitie tor 8TR marker loei: FGA, VWA,
TH01, F13A1, D21 811) and analysed
using quantitative automated DNA sizing
technology. FISH was carried out on inter-
phase nuclei with the use ot probes
speeitie tor X and Y-chromosomes (DXZ 1
and DYZ 1 loei). Results obtained with
the use ot FISH, RT-PCR and STR-PCR
were shown in table.
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